Prospective studies on mite (dermatophagoides farinae) allergen immunotherapy in China

Abstract

Mite allergy study was founded in China beginning in the 1970s and conducted at Shanghai First Medical College. The highest allergenic contents had been detected in comparing the results with those of foreign literature. Around 80% of allergic cases were sensitive to mite allergen by the skin prick tests in concordance with the nasal provocation test and sIgE assay results. Seasonal classic immunotherapy for allergic patients by product Injectio Dermatophagoidei Farinae, the only commercial allergen licensed by the Chinese government, achieved very good results in improving symptoms of allergic disorder in a majority of the cases, in addition, long-lasting effects of mite immunotherapy was also certified with minimal adverse reactions. Studies on sublingual mite vaccine for mite allergic disorders have been synchronized with identified foreign trends since 1992. Sublingual drops are further acceptable for children’s cases almost without age restriction with a high efficacy rate. It has also been shown that rush mite immunotherapy can achieve quick relief of allergic symptoms and long-lasting curative effects.